The US FDA has scheduled a Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) meeting for Wednesday, October 19, 2016, to discuss new drug application (NDA) 201656 for desmopressin, submitted by Serenity Pharmaceuticals, LLC (Serenity) for the proposed treatment of adult onset nocturia. In 2010, Serenity and Allergan, Inc. (Allergan) announced an agreement on its development and commercialization.
See the SAC Tracker report